Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922751 · ClinicalTrials.gov registry record
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
A clinical trial, sponsored by Arbor Research Collaborative for Health.
- Completed
- Registry status
- 552
- Enrollment target
NCT02922751: Completed study, sponsored by Arbor Research Collaborative for Health.
NCT02922751 is a clinical trial that has completed, run by Arbor Research Collaborative for Health. The registered enrollment target is 552 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02922751 has completed, sponsored by Arbor Research Collaborative for Health.
- COMPLETED
- Registry status
- 552 participants
- Enrollment target
Study Summary
Noninvasive monitoring of liver fibrosis is an unmet need within the clinical management of pediatric chronic liver disease. While liver biopsy is often used in the initial diagnostic evaluation, subsequent biopsies are rarely performed because of inherent invasiveness and risks. This study will evaluate the role of non-invasive FibroScan™ technology to detect and quantify liver fibrosis.
Primary Outcome
A linear model will be fit to FibroScan™ values at enrollment to assess the impact of portal hypertension on LSM, controlling for important covariates such as age, gender, and race
Interventions
- OTHER Liver Stiffness Measurement (LSM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2016-11-16 |
| Est. Completion | 2022-12-22 |
What the finished NCT02922751 record still lists
NCT02922751 is an observational study that tracks outcomes without assigning an intervention. The registered 552 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Liver Stiffness Measurement (LSM) is the first listed.
NCT02922751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02922751 about?
NCT02922751 is a clinical study titled "FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)". Noninvasive monitoring of liver fibrosis is an unmet need within the clinical management of pediatric chronic liver disease. While liver biopsy is often used in the initial diagnostic evaluation, subsequent biopsies are rarely performed because of inherent invasiveness and risks. This study will eva...
What is the current status of trial NCT02922751?
This trial is currently completed. The enrollment target is 552 participants. The study started on 2016-11-16. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT02922751?
The interventions under investigation include: Liver Stiffness Measurement (LSM) (OTHER).
Who is sponsoring clinical trial NCT02922751?
This trial is sponsored by Arbor Research Collaborative for Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI